Summit Therapeutics (SMMT) Non Operating Income (2020 - 2026)

Summit Therapeutics (SMMT) has reported Non Operating Income for 7 consecutive years, with $4.8 million the latest figure, recorded in Q2 2026.

• Quarterly Non Operating Income rose 75.74% year-over-year to $4.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $18.8 million (up 19.73% YoY) and the FY2025 annual result came in at $14.8 million, up 10.99% from the prior year.
• Non Operating Income declined to $4.8 million in Q2 2026 per SMMT's latest filing, from $5.8 million in the prior quarter.
• Over the last five years, Non Operating Income for SMMT reached as high as $16.1 million in Q4 2023 and fell as low as -$5.2 million in Q1 2023.
• A 5-year average of $2.6 million and a median of $2.6 million in 2025 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2022 — Non Operating Income plunged 3833.63% — and 2024, when it jumped 689.95%.
• Year by year, Non Operating Income stood at $5.5 million in 2022, then surged by 194.35% to $16.1 million in 2023, then sank by 72.55% to $4.4 million in 2024, then jumped by 30.16% to $5.8 million in 2025, then dropped by 16.63% to $4.8 million in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered $4.8 million, $5.8 million, and $5.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.